University of California LA
Welcome,         Profile    Billing    Logout  
 5 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Szilagyi, Peter
NCT03609242: The STOP-HPV Trial 4: Bundle Intervention

Recruiting
N/A
48
US
STOP-HPV bundle intervention
University of California, Los Angeles, Children's Hospital of Philadelphia, American Academy of Pediatrics, University of Pennsylvania, National Institutes of Health (NIH), National Cancer Institute (NCI), University of Rochester
Immunization, Vaccination
03/21
03/21
STOP-HPV, NCT03599583: The Trial 3: Prompts Intervention

Active, not recruiting
N/A
48
US
STOP-HPV prompts intervention
University of California, Los Angeles, Children's Hospital of Philadelphia, American Academy of Pediatrics, University of Pennsylvania, National Institutes of Health (NIH), National Cancer Institute (NCI), University of Rochester
Immunization, Vaccination
07/22
07/22
NCT03609320: The STOP-HPV Trial 5: Single Arm Evaluation of the Bundle

Active, not recruiting
N/A
24
US
The STOP-HPV Trial 5: Bundle Intervention
University of California, Los Angeles, Children's Hospital of Philadelphia, American Academy of Pediatrics, University of Pennsylvania, National Institutes of Health (NIH), National Cancer Institute (NCI), University of Rochester
Immunization, Vaccination
08/22
08/22
NCT05525494: Patient Portal Flu Vaccine Reminders (5)

Completed
N/A
262085
US
Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link, Portal Fixed R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder
University of California, Los Angeles, National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Respiratory Tract Infections
04/23
04/23
LADHS, NCT05535777: Patient Portal Flu Vaccine Reminders_RCT 5

Completed
N/A
246295
US
Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts
University of California, Los Angeles, National Institute of Allergy and Infectious Diseases (NIAID), Los Angeles County Department of Public Health
Influenza, Respiratory Tract Infections
03/23
03/23
NCT06062264: Patient Portal Flu Vaccine Reminders (RCT 6)

Completed
N/A
22233
US
Portal-based Video Message, Portal-based Infographic Message
University of California, Los Angeles, National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Respiratory Tract Infections
04/24
04/24
NCT04722822: The HPV 9-10 Trial: Early Initiation of HPV Vaccination

Recruiting
N/A
660
US
(Intervention) Recommending HPV vaccine for patients 9-10 years of age, (Control) Recommending HPV vaccine for patients 11-12 years of age
University of Colorado, Denver, National Institutes of Health (NIH), National Cancer Institute (NCI)
HPV
04/25
04/25
Boctor, Kirllos
NCT05462873: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Active, not recruiting
1
30
Europe, Japan, US, RoW
QEQ278
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
02/25
02/25
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29
Sahakian, Lori
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Recruiting
1/2
30
US, RoW
IMPT-514
ImmPACT Bio
Systemic Lupus Erythematosus, Lupus Nephritis
02/27
02/27
Martinez, Carla
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE

Recruiting
N/A
200
US
Decision Support Test
Ampel BioSolutions, LLC
Lupus Erythematosus, Systemic
12/24
03/25
Rodriguez, Janette
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
Karaguezian, Garen
NCT04857372: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

Recruiting
1
156
Europe, Canada, Japan, US, RoW
IAG933
Novartis Pharmaceuticals
Mesothelioma
09/26
09/26

Download Options